Skip to Main Content

Paper Details

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Sci Transl Med
97
2018
-, -mutant cells, AKT, AZD6244, DT, DT-, KRAS, KRAS-, KRAS-driven lung cancer, KRAS-mutant cells, KRAS-mutant lung cancer cell, KRAS-mutant lung cancer cells, MEK, MYC, PP2A, PP2A-inhibited cells, cancer, cancer cell, inhibited cells, mTOR, mammalian target of rapamycin, mitogen-activated protein kinase kinase, mouse, protein phosphatase 2A, rapamycin, serine, serine/threonine phosphatase, threonine, tumor
Author NameAffiliation
Caitlin M O'ConnorCase Comprehensive Cancer Center, Case Western Reserve University
Jaya SangodkarIcahn School of Medicine at Mount Sinai
Jaya SangodkarIcahn School of Medicine at Mount Sinai
Sudeh IzadmehrIcahn School of Medicine at Mount Sinai
Michael OhlmeyerIcahn School of Medicine at Mount Sinai
Michael OhlmeyerIcahn School of Medicine at Mount Sinai
Tero AittokallioInstitute for Molecular Medicine Finland, University of Helsinki
Tero AittokallioUniversity of Turku
Krister WennerbergInstitute for Molecular Medicine Finland, University of Helsinki
Goutham NarlaCase Comprehensive Cancer Center, Case Western Reserve University
Goutham NarlaCase Comprehensive Cancer Center, Case Western Reserve University
  • 1 - 11

Datasets

Release 1.2